ROCKVILLE, Md., May 22, 2024
/PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech
company, exclusively focused on the development and potential
commercialization of highly differentiated immunotherapies for the
treatment of cancer, today announced that management will present
at the Jefferies Global Healthcare Conference on June 5, 2024.
Jefferies Global Healthcare Conference
|
Presentation
Time
|
Wednesday, June
5 at 9:30 a.m. EST
|
|
Presenters
|
Raj Kannan, CEO; Louie
Naumovski, Interim CMO
|
|
Webcast link
|
Here
|
|
Meetings
|
One-on-one and small
group meetings: June 5, 2024
|
|
Management
Participants
|
Raj Kannan,
CEO
Joe Skelton,
CFO
Louie Naumovski,
Interim CMO
Tyler Ehler, Senior
Director, Investor Relations
|
The webcast will also be available under "Event Calendar"
on I-Mab's IR website
at https://ir.i-mabbiopharma.com/
For more information, please contact your Jefferies
representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company,
exclusively focused on the development and potential
commercialization of highly differentiated immunotherapies for the
treatment of cancer. I-Mab has established operations in
Rockville, Maryland, and in
San Diego, California. For more
information, please visit https://ir.i-mabbiopharma.com/ and
follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-jefferies-global-healthcare-conference-302150438.html
SOURCE I-Mab Biopharma
